Your browser doesn't support javascript.
loading
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
Dekeyser, Cathérine; Hautekeete, Matthias; Cambron, Melissa; Van Pesch, Vincent; Patti, Francesco; Kuhle, Jens; Khoury, Samia; Lechner Scott, Jeanette; Gerlach, Oliver; Lugaresi, Alessandra; Maimone, Davide; Surcinelli, Andrea; Grammond, Pierre; Kalincik, Tomas; Habek, Mario; Willekens, Barbara; Macdonell, Richard; Lalive, Patrice; Csepany, Tunde; Butzkueven, Helmut; Boz, Cavit; Tomassini, Valentina; Foschi, Matteo; Sánchez-Menoyo, José Luis; Altintas, Ayse; Mrabet, Saloua; Iuliano, Gerardo; Sa, Maria Jose; Alroughani, Raed; Karabudak, Rana; Aguera-Morales, Eduardo; Gray, Orla; de Gans, Koen; van der Walt, Anneke; McCombe, Pamela A; Deri, Norma; Garber, Justin; Al-Asmi, Abdullah; Skibina, Olga; Duquette, Pierre; Cartechini, Elisabetta; Spitaleri, Daniele; Gouider, Riadh; Soysal, Aysun; Van Hijfte, Liesbeth; Slee, Mark; Amato, Maria Pia; Buzzard, Katherine; Laureys, Guy.
Afiliação
  • Dekeyser C; Neurology, University Hospital Ghent, Gent, Belgium catherine.dekeyser@uzgent.be.
  • Hautekeete M; Neurology, University Hospital Ghent, Gent, Belgium.
  • Cambron M; Neurology, Sint-Jan Bruges Hospital, Bruges, Belgium.
  • Van Pesch V; University of Ghent, Ghent, Belgium.
  • Patti F; Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Kuhle J; Université Catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium.
  • Khoury S; Neuroscience, University of Catania Department of Surgical and Medical Sciences and Advanced Technologies 'G.F. Ingrassia', Catania, Italy.
  • Lechner Scott J; Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, Catania, Italy.
  • Gerlach O; Neurology, University Hospital Basel, Basel, Switzerland.
  • Lugaresi A; Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Basel, Switzerland.
  • Maimone D; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.
  • Surcinelli A; Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia.
  • Grammond P; Hunter New England Health, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
  • Kalincik T; Neurology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
  • Habek M; Neurology, Universiteit Maastricht School for Mental Health and Neuroscience, Maastricht, The Netherlands.
  • Willekens B; UOSI Riabilitazione Sclerosi Multipla, IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Macdonell R; Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.
  • Lalive P; Centro Sclerosi Multipla, UOC Neurologia, Azienda Ospedaliera Cannizzaro, Catania, Italy.
  • Csepany T; Department of Neuroscience, MS Center, S Maria delle Croci Hospital, Ravenna, Italy.
  • Butzkueven H; CISSS Chaudière-Appalaches Research Center, Levis, Quebec, Canada.
  • Boz C; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Tomassini V; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Foschi M; University Hospital Centre Zagreb Department of Neurology, Zagreb, Croatia.
  • Sánchez-Menoyo JL; University of Zagreb School of Medicine, Zagreb, Zagreb, Croatia.
  • Altintas A; Neurology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.
  • Mrabet S; Laboratory of Experimental Hematology, Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen, Wilrijk, Belgium.
  • Iuliano G; Austin Health, Melbourne, Victoria, Australia.
  • Sa MJ; Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology, Geneva University Hospitals Department of Medicine, Geneve, Switzerland.
  • Alroughani R; Department of Neurology, University of Debrecen, Debrecen, Hungary.
  • Karabudak R; Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia.
  • Aguera-Morales E; Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.
  • Gray O; Neurology, Karadeniz Technical University, Medical Faculty, Trabzon, Turkey.
  • de Gans K; Istituto di Tecnologie Avanzate Biomediche (ITAB), Dipartimento di Neuroscienze e Imaging e Scienze Cliniche; Centro Sclerosi Multipla, Clinica Neurologica, Ospedale SS Annunziata, Università degli Studi Gabriele d'Annunzio Chieti Pescara, Chieti, Italy.
  • van der Walt A; University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.
  • McCombe PA; Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital, Ravenna, Italy.
  • Deri N; Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, L'Aquila, Italy.
  • Garber J; Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Galdakao, Spain.
  • Al-Asmi A; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Skibina O; Neurology, Koc University School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.
  • Duquette P; Neurology, Razi University Hospital, Clinical Investigation Centre Neurosciences and Mental Health, Tunis, Tunisia.
  • Cartechini E; University of Tunis El Manar Faculty of Medicine of Tunis, Tunis, Tunisia.
  • Spitaleri D; Ospedali Riuniti di Salerno, Salerno, Italy.
  • Gouider R; Neurology, Centro Hospitalar de São João, Porto, Portugal.
  • Soysal A; Fernando Pessoa University Faculty of Health Sciences, Porto, Portugal.
  • Van Hijfte L; Neurology, Amiri Hospital, Kuwait City, Kuwait.
  • Slee M; Neurological Sciences, Yeditepe Universitesi, Istanbul, Turkey.
  • Amato MP; Neuroimmunology, Kosuyolu Hospitals, Istanbul, Turkey.
  • Buzzard K; Neurology, Hospital Universitario Reina Sofia, Cordoba, Spain.
  • Laureys G; GC28 Neuroplasticity and Oxidative Stress, IMIBIC, Cordoba, Spain.
Article em En | MEDLINE | ID: mdl-38569872
ABSTRACT

BACKGROUND:

It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course.

METHODS:

This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis.

RESULTS:

In total, 11 245 participants were included of which 93.7% (n=10 533) were persons with relapsing-remitting MS (RRMS). In RRMS, the presence of CSF oligoclonal bands (OCBs) was associated with shorter time to disability milestones EDSS 4 (adjusted HR=1.272 (95% CI, 1.089 to 1.485), p=0.002), EDSS 6 (HR=1.314 (95% CI, 1.062 to 1.626), p=0.012) and EDSS 7 (HR=1.686 (95% CI, 1.111 to 2.558), p=0.014). On the other hand, the presence of CSF pleocytosis (≥5 cells/µL) increased time to moderate disability (EDSS 4) in RRMS (HR=0.774 (95% CI, 0.632 to 0.948), p=0.013). None of the CSF variables were associated with time to disability milestones in persons with primary progressive MS (PPMS). The presence of CSF pleocytosis increased ARR2 in RRMS (adjusted R2=0.036, p=0.015).

CONCLUSIONS:

In RRMS, the presence of CSF OCBs predicts shorter time to disability milestones, whereas CSF pleocytosis could be protective. This could however not be found in PPMS. CSF pleocytosis is associated with short-term inflammatory disease activity in RRMS. CSF analysis provides prognostic information which could aid in clinical and therapeutic decision-making.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article